idarubicinol has been researched along with idarubicin in 47 studies
| Studies (idarubicinol) | Trials (idarubicinol) | Recent Studies (post-2010) (idarubicinol) | Studies (idarubicin) | Trials (idarubicin) | Recent Studies (post-2010) (idarubicin) |
|---|---|---|---|---|---|
| 54 | 10 | 0 | 1,795 | 454 | 487 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.51) | 18.7374 |
| 1990's | 30 (63.83) | 18.2507 |
| 2000's | 13 (27.66) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ames, MM; Spreafico, F | 1 |
| Ames, MM; Kuffel, MJ; Reid, JM | 1 |
| Camaggi, CM; Carisi, P; Pannuti, F; Strocchi, E | 1 |
| Camaggi, CM; Carisi, P; Efthymiopoulos, C; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E; Strolin-Benedetti, M; Tononi, A | 1 |
| Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J | 1 |
| Ames, MM; Hammond, GD; Krailo, MD; Pendergrass, TW; Reid, JM | 1 |
| Barbui, T; Biondi, A; Catapano, C; D'Incalci, M; Giudici, G; Limonta, M; Masera, G; Specchia, G | 1 |
| D'Incalci, M; Erranti, D; Freshi, A; Tirelli, U; Zanette, L; Zucchetti, M | 1 |
| Bastholt, L; Dalmark, M; Ebbehøj, E; Elbaek, K; Jakobsen, A; Juul, P; Rasmussen, SN; Steiness, E | 1 |
| Eksborg, S; Nilsson, B | 1 |
| de Graaf, SS; Evans, WE; Riley-Stewart, CA | 1 |
| Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V | 1 |
| Cornblatt, B; Doyle, LA; Ross, DD; Tong, Y; Yang, W | 1 |
| Ames, MM; Kuffel, MJ | 1 |
| Fukushima, T; Kawai, Y; Nakamura, T; Ueda, T; Urasaki, Y; Yoshida, A | 1 |
| Biersack, H; Brieden, T; Gieseler, F; Manderscheid, J; Nüssler, V | 1 |
| Boezeman, J; de Witte, T; Haanen, C; Linssen, P; Minderman, H; van der Lely, N; Wessels, J | 1 |
| Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M | 2 |
| Boiocchi, M; Corona, G; De Angeli, S; Gigante, M; Simone, F; Toffoli, G | 1 |
| Paul, C; Prenkert, M; Tidefelt, U | 1 |
| Abbadessa, V; Cajozzo, A; Gancitano, RA; Musso, M; Perricone, R; Porretto, F; Tolomeo, M | 1 |
| Baltes-Engler, S; Dederichs, B; Diehl, V; Engelhard, M; Engert, A; Küpper, F; Lathan, B; Reiser, M; Scheulen, ME; Schnell, R; Tesch, H; Wilhelm, M; Winterhalter, B; Wörmann, B | 1 |
| Linke, R; Looby, M; Weiss, M | 1 |
| Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R | 1 |
| Blaschke, G; Boos, J; Haberland, S; Hempel, G; Möhling, N; Schulze-Westhoff, P | 1 |
| Brieden, T; Gieseler, F; Kunze, J; Nüssler, V; Valsamas, S | 1 |
| Fiallo, M; Gallois, L; Garnier-Suillerot, A | 1 |
| Bondi, F; Crescimanno, A; Mariani, G; Musso, M; Polizzi, V; Porretto, F; Scalone, R; Tolomeo, M | 1 |
| Fukushima, T; Imamura, S; Inai, K; Inoue, H; Kishi, S; Nakamura, T; Nakayama, T; Takemura, H; Ueda, T; Urasaki, Y; Yamauchi, T | 1 |
| Fukushima, T; Imamura, S; Misaki, H; Ueda, T; Urasaki, Y; Yamashita, T; Yamauchi, T; Yoshio, N | 1 |
| Hofmann, S; Kuhlmann, O; Weiss, M | 1 |
| Barbui, T; Bassan, R; Chiodini, B | 1 |
| Kasimir-Bauer, S; Scheulen, ME; Schröder, JK; Seeber, S | 1 |
| Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S | 1 |
| Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G | 1 |
| de Witte, T; Linssen, P; Masereeuw, R; Muus, P; Raymakers, R; Smeets, M; Vierwinden, G | 1 |
| Fukushima, T; Goto, N; Kuraishi, Y; Ogawa, M; Ohno, R; Okabe, KI; Ueda, T; Urabe, A; Yamashita, T | 1 |
| Kang, W; Weiss, M | 2 |
| Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP | 1 |
| Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I | 1 |
| Aita, P; Basso, B; Boiocchi, M; Corona, G; Ruolo, G; Rupolo, M; Sorio, R; Toffoli, G | 1 |
| Giessler, C; Kang, W; Weiss, M | 1 |
| Barbara, C; Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Fioravanti, A; Orlandi, P | 1 |
| Corona, G; Crivellari, D; Lestuzzi, C; Lombardi, D; Lucenti, A; Magri, MD; Massacesi, C; Sorio, R; Talamini, R; Toffoli, G; Veronesi, A | 1 |
1 review(s) available for idarubicinol and idarubicin
| Article | Year |
|---|---|
Selected pharmacologic characteristics of idarubicin and idarubicinol.
Topics: Animals; Daunorubicin; Humans; Idarubicin | 1992 |
9 trial(s) available for idarubicinol and idarubicin
| Article | Year |
|---|---|
Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study.
Topics: Administration, Oral; Biological Availability; Daunorubicin; Glycosylation; Humans; Idarubicin; Infusions, Intravenous; Kidney; Kidney Diseases; Liver Neoplasms; Neoplasms | 1992 |
Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Topics: Administration, Oral; Aged; Biological Availability; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Multicenter Studies as Topic | 1990 |
Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Topics: Adolescent; Adult; Child; Child, Preschool; Daunorubicin; Drug Evaluation; Humans; Idarubicin; Infant; Leukemia | 1990 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged | 1996 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Individuality; Lymphoma, Non-Hodgkin; Male; Middle Aged | 1997 |
Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Chromatography, Liquid; Cross-Over Studies; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Spectrometry, Fluorescence | 1997 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 2000 |
A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
Topics: Aged; Antibiotics, Antineoplastic; Area Under Curve; Biotransformation; Daunorubicin; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Idarubicin; Japan; Leukocyte Count; Leukopenia; Lymphoma; Male; Middle Aged; Neutropenia | 2001 |
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Chromatography, High Pressure Liquid; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Idarubicin; Liver Neoplasms; Lung Neoplasms; Soft Tissue Neoplasms | 2006 |
37 other study(ies) available for idarubicinol and idarubicin
| Article | Year |
|---|---|
Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Topics: Antibiotics, Antineoplastic; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Doxorubicin; Epirubicin; Glioma; Humans; Idarubicin; Leukemia, Myeloid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1992 |
High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.
Topics: Calibration; Chromatography, High Pressure Liquid; Daunorubicin; Fluorescence; Humans; Idarubicin; Reference Standards | 1992 |
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.
Topics: Adult; Antineoplastic Agents; Cell Division; Daunorubicin; DNA Damage; DNA, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Daunorubicin; Female; Half-Life; Humans; Idarubicin; Injections, Intravenous; Male; Middle Aged; Neoplasms | 1990 |
Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Topics: Administration, Oral; Aged; Biological Availability; Breast Neoplasms; Daunorubicin; Half-Life; Humans; Idarubicin; Male; Middle Aged | 1989 |
Reversed-phase liquid chromatographic determination of idarubicin and its 13-hydroxy metabolite in human plasma.
Topics: Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Daunorubicin; Humans; Hydrogen-Ion Concentration; Idarubicin; Spectrometry, Fluorescence | 1989 |
Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma.
Topics: Chromatography, High Pressure Liquid; Daunorubicin; Humans; Idarubicin; Time Factors | 1989 |
Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Topics: Antibiotics, Antineoplastic; Biotransformation; Daunorubicin; Humans; Idarubicin; Injections, Intravenous; Kinetics; Leukemia, Myeloid, Acute | 1987 |
Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Breast Neoplasms; Cell Survival; Culture Media; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; HL-60 Cells; Humans; Idarubicin; Intracellular Fluid; Tumor Cells, Cultured | 1995 |
Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Mice; Transfection | 1995 |
Influence of idarubicinol on the antileukemic effect of idarubicin.
Topics: Daunorubicin; DNA; DNA Damage; Humans; Idarubicin; In Vitro Techniques; Leukemia, Myeloid; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured | 1994 |
Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Nucleus; Cell Survival; Daunorubicin; DNA; Humans; Idarubicin; Lethal Dose 50; Lymphocytes; Tumor Cells, Cultured | 1994 |
Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
Topics: Acute Disease; Antineoplastic Agents; Cell Division; Daunorubicin; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Macrophages; Tumor Stem Cell Assay | 1994 |
Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Topics: Acute Disease; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 1994 |
Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; Tumor Cells, Cultured | 1996 |
Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin | 1996 |
Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Idarubicin; Immunosuppressive Agents; Tumor Cells, Cultured | 1996 |
Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Topics: Animals; Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Daunorubicin; Idarubicin; Rabbits; Tissue Distribution | 1997 |
Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
Topics: Antibiotics, Antineoplastic; Child; Daunorubicin; Electrophoresis, Capillary; Humans; Idarubicin; Reference Standards | 1997 |
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Chromatography, High Pressure Liquid; Daunorubicin; Half-Life; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged; Regression Analysis | 1997 |
Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Nucleus; Daunorubicin; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Idarubicin; Leukemia | 1998 |
Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study.
Topics: Anthracyclines; Circular Dichroism; Daunorubicin; Dimerization; Doxorubicin; Idarubicin; Lipid Bilayers; Liposomes; Membranes, Artificial; Models, Molecular; Solvents | 1998 |
Only association of low concentrations of idarubicin plus idarubicinol induced apoptosis on leukaemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Daunorubicin; HL-60 Cells; Humans; Idarubicin | 1998 |
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Topics: Antineoplastic Agents; Cell Division; Cell Extracts; Cell Survival; Cytotoxins; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Idarubicin; Trypan Blue; Tumor Cells, Cultured | 1998 |
Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; K562 Cells | 1999 |
Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.
Topics: Animals; Antibiotics, Antineoplastic; Chromatography, High Pressure Liquid; Daunorubicin; Idarubicin; Male; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 1999 |
Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells.
Topics: Annexin A5; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Genes, MDR; Humans; Idarubicin; Leukemia-Lymphoma, Adult T-Cell; Membrane Lipids; Necrosis; Phosphatidylserines; Tumor Cells, Cultured | 1999 |
In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Topics: Antineoplastic Agents; Blast Crisis; Calcium Channel Blockers; Daunorubicin; Dihydropyridines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Tumor Cells, Cultured; Verapamil | 2000 |
Induction of apoptosis by idarubicin: how important is the plasma peak?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Area Under Curve; Daunorubicin; DNA, Neoplasm; HL-60 Cells; Humans; Idarubicin; Leukemia, Promyelocytic, Acute | 2000 |
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Female; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence | 2001 |
Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.
Topics: Algorithms; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Heart; Idarubicin; In Vitro Techniques; Male; Myocardium; Rats; Rats, Sprague-Dawley; Stroke Volume; Verapamil | 2001 |
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
Topics: Animals; Antibiotics, Antineoplastic; Daunorubicin; Drug Administration Routes; Drug Carriers; Duodenum; Idarubicin; Nanotechnology; Rats; Rats, Wistar; Solutions; Tissue Distribution | 2002 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Daunorubicin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Idarubicin; Melphalan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Taxoids; Thiotepa; Time Factors; Transplantation Conditioning; Treatment Outcome | 2003 |
Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital.
Topics: Amiodarone; Animals; Antineoplastic Agents; Daunorubicin; Drug Design; Excitatory Amino Acid Antagonists; Heart; Idarubicin; Kinetics; Male; Phenobarbital; Rats; Rats, Sprague-Dawley; Rutin; Time Factors; Vasodilator Agents; Verapamil | 2003 |
Pharmacokinetic comparison of 120-hour infusion versus hyperfractionated oral administration of idarubicin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Area Under Curve; Daunorubicin; Female; Humans; Idarubicin; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2004 |
Effects of idarubicin and idarubicinol on rat coronary resistance and vasoconstrictor responsiveness of isolated aorta and mesentery.
Topics: Animals; Antibiotics, Antineoplastic; Aorta, Thoracic; Coronary Circulation; Daunorubicin; Dose-Response Relationship, Drug; Heart; Idarubicin; In Vitro Techniques; Inhibitory Concentration 50; Male; Mesenteric Arteries; Muscle, Smooth, Vascular; Norepinephrine; Phenylephrine; Potassium Chloride; Rats; Rats, Wistar; Vascular Resistance; Vasoconstriction; Vasoconstrictor Agents | 2006 |
Idarubicin and idarubicinol effects on breast cancer multicellular spheroids.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Inhibitory Concentration 50; Spheroids, Cellular; Time Factors | 2005 |